Investor Relations

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products utilizing the FDA's 505(b)(2) regulatory pathway.

Eton has a diversified pipeline of product candidates under development across various liquid dosage forms, including injectables, oral liquids, and ophthalmics.

Volume :

Copyright West LLC. Minimum 15 minutes delayed.

News Releases
May 14, 2020
DEER PARK, Ill. , May 14, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported financial results for the first quarter ended March 31, 2020 and provided an update on
May 7, 2020
- Eton confirms first-to-file ANDA referencing Exela Pharma Sciences’ Elcys product - Eton plans to file Post Grant Reviews in the U.S. Patent & Trademark Office challenging the validity of Exela’s listed patents, which, if successful, could allow Eton to launch in 2021 - Eton believes Exela Pharma
May 6, 2020
DEER PARK, Ill. , May 06, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report first quarter 2020 financial and operating results on Thursday, May

Eton
Latest Event

Eton Pharma Reports Positive Top-Line Results from Phase III Trial of EM-100 Ophthalmic Solution
More events are coming soon.